Synta Pharmaceuticals says that a Phase IIb clinical trial of STA-4783 doubled the progression free survival time of volunteers with metastatic melanoma in the study, hitting the study's primary endpoint for statistical significance. Median PFS for patients receiving STA-4783 plus paclitaxel was 112 days versus 56 days for those receiving paclitaxel alone. Report